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ABSTRACT
Background
The use of mega-vitamin intervention began in the 1950s with the treatment of schizophrenic patients. Pyroxidine (vitamin B6) was
first used with children diagnosed with “autism syndrome” when speech and language improvement was observed in some children as
a result of large doses of B6. A number of studies attempted to assess the effects of vitamin B6-Magnesium (Mg) was found to reduce
undesirable side effects from B6) on characteristics such as verbal communication, non-verbal communication, interpersonal skills, and
physiological function, in individuals with autism.
Objectives
To determine the efficacy of vitamin B6 and magnesium (B6-Mg) for treating social, communication, and behavioural responses of
children and adults with autism.
Search methods
We searched the Cochrane Controlled Trials Register (Cochrane Library, Issue 1, 2005), MEDLINE (1966 to April 2005), EMBASE
(1980 to April 2005), PsycINFO (1887 to April 2005), Dissertation Abstracts International (1861 to April 2005). The search engine
FirstSearch was also used (April 2005). Reference lists for all the obtained studies and other review articles were examined for additional
studies.
Selection criteria
All studies in which the participants had been diagnosed with autistic spectrum disorder were randomly allocated prior to intervention
and in which outcomes were compared to either a placebo or non-treated group were included.
Data collection and analysis
Two reviewers independently evaluated and extracted data from all potential studies identified for inclusion.
Main results
The 2005 update includes a new trial (Kuriyama 2002) to bring the total of included studies to three (total n=33). One study, which
used a cross-over design (Tolbert 1993) provided insufficient data to conduct an analysis. Another crossover study (Findling 1997)
yielded no significant differences between treatment and placebo group performances following the B6 intervention on measures of
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social interaction, communication, compulsivity, impulsivity, or hyperactivity. The latest study (Kuriyama 2002) was motivated by
evidence from epilepsy research and was focussed on a subgroup of children with pervasive developmental disorders (PDDs) who
exhibited clinical features similar to those with pyroxidine-dependent epilepsy. This small study (n=8) only measured IQ and ’Social
Quotient’ and found a statistically significant benefit for IQ (5.2, 95% CI = [0.2 to 10.3]) when in the treated group, by using change
scores.
Authors’ conclusions
Due to the small number of studies, the methodological quality of studies, and small sample sizes, no recommendation can be advanced
regarding the use of B6-Mg as a treatment for autism.

PLAIN LANGUAGE SUMMARY
Vitamin B6 and magnesium in combination for children with autism spectrum disorder
Studies investigating the effect of vitamin B6 in improving the behaviour of children with autism spectrum disorder have been reported
for over three decades. The purpose of this review was to summarize those studies and analyse the effectiveness of vitamin B6 as an
intervention. Only three studies met the inclusion criteria of this review and of these only one study reported adequate data for analysis.
Results were inconclusive and sample sizes were small. Therefore the use of vitamin B6 for improving the behaviour of individuals with
autism cannot currently be supported. Further research using larger, well-designed trials is needed.

BACKGROUND

Description of the condition
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), autism is defined by significant deficits in social
interaction, communication, and stereotypical behaviour patterns
(APA 1994). The impairments in social interactions may result in
such behaviours as isolation from others, withdrawal from socialising activities, and/or lack of development of play skills. Communication deficits centre on the inability to use expressive language
appropriately, understand the rules of communicative exchange,
and/or a lack of comprehension of the meaning of non-verbal language. Stereotypical behaviour patterns are seen in repetitive motor activity, engagement in ritualistic behaviours, and/or an exaggerated focus on parts of objects. A review and update of epidemiological studies published between 1966 and 2003 show reports
of the estimated prevalence for autism has varied between 0.7 and
40 children per 10,000 (Fombonne 1999, Fombonne 2003).

Pyridoxine (vitamin B6) was first reported to improve speech and
language in some children diagnosed with “autism syndrome”
when Bönisch observed that some participants showed improvement in speech and language (Bönisch 1968). Other researchers
(Ananth 1973; Bucci 1973; Greenberg 1970) also reported improved behavioural or biochemical functioning with schizophrenic
participants given large doses of vitamin B6. These studies, along
with individual anecdotal observations of parents and professionals, led Rimland and colleagues (Rimland 1978) to assess the effectiveness of this orthomolecular treatment. Rimland had recognised that large doses of vitamin B6 produced several undesirable side effects (including irritability, hypersensitivity to sound
and enuresis, which could be countered with doses of magnesium
[Mg]). Over the next 19 years, a number of investigators published
studies in which attempts had been made to assess the effects of
vitamin B6-Mg on a variety of characteristics such as verbal communication, non-verbal communication, interpersonal skills, and
physiological function, in individuals with autism.

Why it is important to do this review
Description of the intervention
The use of mega-vitamin intervention began in the early 1950s
with the treatment of schizophrenic patients (Rimland 1964).

The published research included five double-blind crossover trials (Barthelemy 1980; Barthelemy 1981; Jonas 1984; Martineau
1985; Rimland 1978), eight non-randomized trials (Barthelemy
1985; Bönisch 1968; Lelord 1978; Martineau 1981; Martineau
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1982; Martineau 1988; Martineau 1989; Menage 1992), two
trials using open and double blind arms in their investigations
(Lelord 1981; Lelord 1982), and three randomized double-blind
placebo controlled trials (Tolbert 1993; Findling 1997, Kuriyama
2002). Non-randomized studies Rimland, Callaway and Dreyfus
(Rimland 1978) reported a double-blind non-randomized study
in which 16 “autistic type” children were treated with large doses of
B6-Mg for varying periods of time and then withdrawn. The analysis of the data suggested that the behavioural changes were significant. However, Rimland et al failed to make a strong statement
of advocacy for the B6-Mg regimen as a therapeutic intervention.
This early study is noteworthy for the lack of methodological and
statistical rigor for even the most generous of interpretations of
the data.
Others (Barthelemy 1980; Barthelemy 1981; Jonas 1984;
Martineau 1985) conducted double-blind crossover trials assessing
behavioural, physiological, electrophysiological, and/or communicative functioning. Conclusions from these studies offer varying statements of support for the study and use of B6-Mg using terms such as ’promising’, ’significant’, ’tendency toward normal’, and often call for additional study. Lelord and colleagues
(Lelord 1981; Lelord 1982) utilised a combined open and doubleblind crossover trial to measure the effects of B6-Mg therapy with
autistic children in assessing behavioural, biochemical, and electrophysiological parameters. The methodological design of these
studies required that the initial sample of participants was administered a B6-Mg procedure with dependent measures taken. After
“several months”, a subset of participants called ’responders’ and
’non-responders’ was investigated further in a new non-randomized double-blind crossover study. The results of the double-blind
crossover trial indicated significant improvements in the treated
participants as evidenced by their regression to pre-treatment levels when the intervention was removed.
The eight open non-randomized trials (Barthelemy 1985; Bönisch
1968; Lelord 1978; Martineau 1981; Martineau 1982; Martineau
1988; Martineau 1989; Menage 1992) used a variety of methodologies including completely open trials, normal comparison participants, non-treated autistic participants or pre-treatment and
post-treatment of a single, experimental group. As with the other
non-randomized trials, the data from these investigations generally supported the use and/or further investigation of the use of
B6-Mg in the treatment of autistic children.
It was not until Tolbert (Tolbert 1993) and Findling (Findling
1997) conducted randomized double-blind placebo-controlled
studies that contrary results emerged. Using different rating scales
to measure the behavioural outcomes of the B6-Mg intervention,
both of these studies suggested that there was no statistically significant effect from the use of B6-Mg for improved behavioural outcomes in children with autism. However, Tolbert (Tolbert 1993)
used lower doses of vitamin B6-Mg and concluded that they
did not necessarily contradict earlier studies (Lelord 1982; Lelord
1982; Martineau 1981; Martineau 1985; Martineau 1988). Pfeif-

fer, Norton, Nelson, and Schott (Pfeiffer 1996) provided a narrative summary of the vitamin B6 research with autism that included 12 studies published up to 1989. Though Pfeiffer et al
identified issues such as design, participant selection, treatment
parameters and measurement differences, it was concluded that
“B6-Mg treatment may be a promising adjunct in the treatment of
autism” (p.491). Following previous research in children with pervasive developmental disorders (PDDs) who experienced epileptic seizures and for whom pyroxidine appeared to prevent seizures
and raise intelligent quotient (IQ) scores, investigators in a recent
trial (Kuriyama 2002) hypothesised that another subgroup (children diagnosed with PDDs who also exhibited clinical features
similar to those with pyroxidine-dependent epilepsy, but did not
have seizures) might benefit. The study recruited children who
were higher-functioning than was typical in other groups, and only
measured IQ and ’Social Quotient’.
The purpose of this systematic review was to assess the efficacy
of B6-Mg treatment of individuals with autism spectrum disorders (ASD) for social interaction, communication, and stereotypical behavioural performance. Positive effects of B6-Mg intervention would result in improved verbal skills, non-verbal skills, social interaction skills, and reactions to environmental stimuli and
changes.

OBJECTIVES
To determine the efficacy of vitamin B6 and magnesium (B6-Mg)
for treating social, communication, and behavioural responses of
children and adults with autism spectrum disorder.

METHODS

Criteria for considering studies for this review

Types of studies
All randomized trials in which individuals with autism were administered vitamin B6-Mg were included in the review. The control groups included groups of individuals with a diagnosis of
autism who received either placebo or no treatment.
Types of participants
Adults or children with ASD. ASD included pervasive developmental disorders (as described in DSM-IV [APA 1994] and ICD10
[WHO 1993] or diagnosed using a standard diagnostic instrument, eg the Childhood Autism Rating Scale (CARS) (Schopler
1980).
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Types of interventions
The treatment studied was combined vitamin B6 with Mg, taken
in tablet or powder form for a minimum of one week and a maximum of 52 weeks.
Types of outcome measures
The major outcome measures included measures of:
1. Verbal Behaviour: e.g. increased language usage;
2. Non-verbal Behaviour: e.g. improved response to environmental stimuli;
3. Social interaction: e.g. increased response to people.
Where possible, outcomes were examined with respect to the
length of treatment i.e. short term (2 weeks) medium term (6 to
12 weeks) and long term (13 weeks and more). We also examined
outcomes for any follow-up periods included in studies.

Search methods for identification of studies
Search strategy for identification of studies
The following databases were searched: the Cochrane Controlled
Trials Register CENTRAL (The Cochrane Library, Issue 2, 2002,
updated search run on 2005 Issue 2), MEDLINE (1966 to January 2002, updated search run to April week 3 2005), EMBASE
(1980 to January 2002, updated search run to 2005 week 18),
PsycINFO (1887 to January 2002, updated search run to April
week 3 2005), Dissertation Abstracts International, (1861 to January 2002, updated search run to April 2005). The search engine
FirstSearch was also used (January 2002). All issues of the Journal
of Autism and Developmental Disabilities were also handsearched.
In addition, the reference lists for all of the obtained studies and
other review articles were examined for additional studies. Fulltext copies of all potentially appropriate citations were obtained.
The following search strategy was used to search the Cochrane
Controlled Trials Register and amended where appropriate for the
other databases:
1) CHILD-DEVELOPMENT-DISORDERS-PERVASIVE*:
ME
2) SPEECH-DISORDERS*:ME
3) AUTIS*
4) (PERVASIVE and (DEVELOPMENTAL and DISORDER*))
5) PDD
6) (LANGUAGE next DELAY*)
7) ((COMMUNICAT* or SPEECH) next DISORDER*)
8) (CHILDHOOD next SCHIZOPHRENIA)
9) KANNER*
10) ASPERG*
11) (((((((((#1 or #2) or #3) or #4) or #5) or #6) or #7) or #8) or
#9) or #10)
12) B6
13) PYRIDOXINE
14) MAGNESIUM

15) VITAMIN-B-COMPLEX*:ME
16) MAGNESIUM*:ME
17) VITAMIN-B6
18) VITAMIN-B
19) (((((#12 or #13) or #14) or #15) or #16) or #17)
20) (#11 and #19)
No language restrictions were applied. A filter to capture randomized controlled trials was used when appropriate.

Data collection and analysis

Selection of studies
All potential studies identified were independently evaluated for
inclusion by two primary reviewers (Chad Nye [CN]) and Alejandro Brice [AB]). When questions arose as to the possible inclusion/
exclusion of any individual study, a final consensus decision was
reached by discussion between CN and AB. Provision was made
for a third reviewer if consensus was unattainable, however, there
were no studies requiring participation of the additional reviewer.
The primary reviewers were not blind to author(s), institution(s),
or publication source at any time during the selection process.
Data extraction and management
Each reviewer independently extracted the data for each study
meeting the inclusion criteria identified above. In the event that
insufficient data were available, the first author was contacted to
provide data and clarification. If the requested data were made
available and determined to be appropriate to the review, they
were extracted and included. If the data were unavailable or otherwise inadequate, the study was reported but not included in the
final data analysis. All studies meeting the inclusion criteria are
summarized in the ’Included Studies’ table. Comments on design,
participants, interventions, and outcomes are included.
Assessment of risk of bias in included studies

Assessment of methodological quality

The categorization of methodological quality included consideration of the allocation concealment. Each study was assigned to
one of three categories of methodological quality described in the
Cochrane Reviewers’ Handbook by both CN and AB (Alderson
2004).
These categories are:
A - adequate concealment, B - unclear concealment and C - inadequate concealment. Adequate concealment included any form
of random assignment in which the individual participant’s group
assignment was unknown prior to the actual assignment and an
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acceptable randomization procedure such as computer-generated
allocation was used for group assignment. If the author(s) of the
study indicated that participant assignment to the experimental
and control conditions was accomplished using a randomized process but gave no specific information regarding the details of the
randomizing process, that study would at best be classified as using
an unclear concealment procedure. Only studies reporting adequate or unclear concealment were assigned to the included studies group. Studies reporting no randomizing procedure were automatically categorized as reflecting an inadequate concealment
procedure and were not included for the review or analysis. As
indicated in the protocol, it was decided that no study reporting
more than 20% attrition would be assigned to the included studies
group.
Assessment of heterogeneity
No meta-analysis is possible for the current version of this review, due to lack of reported data (Findling 1997) and differences in both clinical populations and outcome measures between
Kuriyama 2002 and Tolbert 1993. Should sufficient data be available at future updates, consistency of results will be assessed visually and by examining I2 , a quantity which describes approximately the proportion of variation in point estimates that is due
to heterogeneity rather than sampling error (Higgins 2002). This
will be supplemented with a test of homogeneity to determine the
strength of evidence that the heterogeneity is genuine.
Data synthesis
No meta-analysis was possible in the original or updated version
of this review. Should sufficient data be obtained at future updates
of this review, data analysis will be conducted using RevMan 4.2.
For dichotomous data, such as number of children with improved
behaviour, an odds ratio and a 95% confidence interval will be
the statistic calculated. For continuous data, such as improvement
of language test scores, a weighted mean difference will be used
when the outcomes are measured in a standard way across different
studies. When continuous data are from different but conceptually
similar measures, such as different tests of language performance,
a standardized mean difference statistic will be employed.
Sensitivity analysis
Neither sensitivity analyses nor subgroup analysis were viable options to assess the impact of study quality, clinical differences in
the intervention, or clinically relevant differences between subject
groups, such as age or clinical subgroupings, in the current version
of this review.

RESULTS

Description of studies
A total of 58 abstracts were identified via the electronic and hand
search strategy in original searches conducted in 2002. Of these, 41
were found to be ineligible for inclusion due to inappropriate topic,
duplicate citations, or non-data based papers (e.g. reviews, topic
discussions), and 15 were found to be ineligible for inclusion due
to the use of a non-randomized controlled trial design. The two
remaining studies met inclusion criteria (Tolbert 1993; Findling
1997). At the 2005 update, a total of 27 abstracts were identified
via the electronic search strategy. Of these, one study met inclusion
criteria (Kuriyama 2002).

General features of included studies
Included studies were published between 1993 and 2002. Two
studies were conducted in the USA (Tolbert 1993; Findling 1997)
and one in Japan (Kuriyama 2002). Twenty-three boys and ten girls
took part. Diagnostic methods varied from DSM-III-R (Tolbert
1993) to the CARS (Schopler 1980) (Findling 1997) to DSM-IV
criteria for PDDs (Kuriyama 2002). Administration of the intervention varied from 4 to 20 weeks. Dosage varied from 100mg
B6 rising to 200mg per day after two weeks (Kuriyama 2002)
(no magnesium use reported) to 200mg/70kg of B6 plus 100mg/
70kg of magnesium (Tolbert 1993); to the higher dose of 30mg/kg
body weight (maximum of 1 gram/day) and 10mg/kg body weight
(maximum 350mg/day) (Findling 1997). Outcomes measured included behavioural ones (Tolbert 1993, Findling 1997), social
functioning (Findling 1997, Kuriyama 2002) and IQ (Kuriyama
2002).

Tolbert 1993

Tolbert 1993 used a double-blind placebo-controlled asymmetric crossover with random assignment design where Experimental Group 1’s order of treatment was TTP (treatment-treatmentplacebo) while Experimental Group 2’s order of treatment was
TPT (treatment-placebo-treatment). In addition, Tolbert used a
control group that received neither the placebo nor the B6 and
magnesium. No participant attrition was reported. Following a
five-week no-treatment baseline run-in period, half of the participants received active treatment for 20 consecutive weeks followed
by 10 weeks of placebo. The other half of the participants received
active treatment in 2 blocks of 10 weeks with a 10-week block
of placebo treatment in between the active treatment blocks. A
control group received no treatment at all during the treatment
period. The dosage levels were 200mg/70kg of vitamin B6 and
100mg/70kg of magnesium. Tolbert reported a total participant
sample of 15 males and 5 females with chronological ages ranging from 6 to 18 years, mental ages ranging from 2.0 to 6.7 years
and IQ scores from less than 20 to 65. All participants met the
diagnostic standards of DSM-III-R as measured by child psychiatrists. Five of the male subjects served as non-treated controls and
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were recruited from families that had opted not to participate in
the pharmacological aspect of the trial but did agree to participate
in the behavioural rating component of the trial. All participants
were living in residential settings at the time of the study.
The outcome measures reported by Tolbert were taken from the
Ritvo-Freeman Real Life Rating Scale for Autism (R-F) (Freeman
1986). This measure was used to assess the behavioural changes as
observed in a classroom situation. The R-F measures behaviours
in: (1) sensory motor, (2) social, (3) affective, (4) sensory responses,
and (5) language. The measure of change is obtained by summing
subscale scores. Higher scores indicated a greater presence ofsymptoms during intervention. Data for all outcomes were continuous. Average inter-rater reliability 94.2% (range 70 to100%) was
achieved for the R-F scale observational scoring.

Findling 1997

Findling et al administered a two-week single-blind placebo prior
to initiating the randomized eight-week double-blind placebocontrolled crossover component of the study (Findling 1997). A
total of 12 participants (11 males, 1 female; mean age=77 mo,
range=36 to 155 mo) were enrolled in the study. At the conclusion of the two-week placebo baseline, two subjects were dropped
from the study due to their inability to swallow the encapsulated
medications leaving 10 participants (9 males, 1 female; mean age=
73 mo, range= 36 to155 mo) for the treatment portion of the
study. Beginning with week three of the study, the 10 remaining
participants were randomly assigned to either the experimental
condition receiving the B6-Mg or to the control condition receiving a placebo. Beginning with week seven, the participant groups
were switched with each receiving the other intervention (B6-Mg
versus placebo). No washout time elapsed between the end of the
first four-week condition and the beginning of the second fourweek condition. The dosage level for B6 and Mg was 30mg/kg
body weight (maximum of 1 gram/day) and 10mg/kg body weight
(maximum 350mg/day), respectively. Participants for this study
met the diagnostic standards of DSM-III-R as measured by a certified child psychiatrist and child neurologist.
A pre-treatment measure reported by Findling for this study, the
Childhood Autism Rating Scale (CARS) (Schopler 1980; DiLalla
1994), was used to verify participants’ diagnostic classification of
autism. Prior to the initiation of treatment, and weekly thereafter
during the study, the following measures were administered to
each participant: (1) The Clinical Global Impression Scale (CGI)
(NIMH 1985), (2) Children’s Psychiatric Rating Scale (CPRS)
(Campbell 1985; Overall 1988), (3) Global Obsessive Compulsive
Scale (OCS) (Insel 1983), (4) Conners Parent Rating Scale (PRS)
(Goyette 1978), and (5) Conners Teacher Rating Scale (TRS)
(Goyette 1978). The CARS is a 15-item scale designed to distinguish between mild to moderate and severe behavioural expressions, the CGI, CPRS, and OCS are all measures reflecting the
degree of psychopathology. The PRS and TRS are measures of

parent and teacher observations.

Kuriyama 2002

Kuriyama 2002 recruited 15 children diagnosed with PDDs to
participate in the study of pyridoxine (vitamin B6) versus a
placebo. Two participants were excluded because of current use
of B6, two had a history of epilepsy, and three were unable to
be tested for baseline IQ. The remaining eight children (8 to 12
years of age) were randomly assigned to either an experimental or
placebo condition and administered both the pretest and posttest
measures. In each group one child was diagnosed with Asperger
Syndrome and three children were diagnosed with Pervasive Developmental Disorder Not Otherwise Specified (PDDNOS). The
treatment program consisted of B6 administered in 100mg dose
once each day for two weeks followed by two weeks of twice daily
doses. Outcomes for this study included a measure of intelligence
(Wechsler Intelligence Scale for Children-III) and social intelligence (Social Maturity Scale).

Risk of bias in included studies
Three studies (Findling 1997; Kuriyama 2002; Tolbert 1993) were
identified as meeting the inclusion criteria. All studies reported
randomly assigning participants to the experimental and control
conditions. No study provided a clear description of the method
of participant assignment. All senior authors were contacted for
additional information regarding the randomization procedure.
Tolbert (Tolbert 1993) could not provide additional information
on the randomization procedure while Findling (Findling 1997)
reported that all subjects were randomly assigned at the conclusion
of a two-week baseline period but could not provide specific details of the randomization procedure; information is awaited from
Kuriyama et al (Kuriyama 2002).
Tolbert et al reported a single-blind condition in which parents/
guardians were given a two-week supply of placebo. Following the
baseline, subjects were randomized into the double-blind portion
of the study (Tolbert 1993). Findling et al reported a double-blind
assignment to treatment and control conditions (Findling 1997).
Neither study reported any participant attrition. Kuriyama et al
(Kuriyama 2002) had no ’run-up’ period and reported blinding
of participants, investigators, outcome assessors and statisticians.
There was no loss to follow-up reported for this study.

Effects of interventions
No meta-analysis is possible in the current version of this review.
One study (Tolbert 1993) presented data in a form unsuitable for
meta-analysis. Diversity of participants and clinical populations
and inconsistent use of outcome measures across remaining studies, mean that no synthesis of data is suitable for meta-analysis.
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Tolbert 1993
Tolbert et al reported only an omnibus F-test and p value as a
summary of the data for his study (Tolbert 1993). A Treatment x
Phase analysis yielded a significant reduction across the four treatment phases (F(3,51)=6.17, p=.001). Non-significant differences
were reported for both treatment effects (F(2,17)=1.3, p>.2) and
interaction (F(6,61)=0.25, p>2 (i.e. placebo and treatment phases
all showed an improvement but no difference in improvement
was seen for treatment when compared to placebo). Standard deviations and means (such as are necessary to use in meta-analysis
performed in RevMan) were not provided in the published paper.
When contacted to provide additional appropriate data to include
in the analysis, Dr Tolbert was unable to locate the data; therefore
this study was not included in the analysis of data for this review.
Findling 1997
Findling et al (Findling 1997) provided appropriate group means
and standard deviations for data for analysis of five measures of
behavioural performance during the treatment program, none of
which showed a significant difference. Behaviours associated with
individuals with autism CPRS was used as an assessment of behaviour in children with autism including social interactions, communication skills, and level of physical activity. At two weeks posttreatment onset, no significant differences between the experimental and control groups emerged (2.70, 95% CI= -6.29, 11.69). An
analysis of the data as printed in the published paper for this outcome at four weeks post-treatment onset yields a significant difference in favour of the treated group ( -28.00, 95% CI= -37.25,
-18.75); however, these data (which include a score of 3.2 when
values at all other points are closer to 32) are in conflict with the
triallists’ own analysis, which did not report a significant change.
Triallists have been contacted but any further information or data
are reported to be unavailable.
Compulsive Behaviour (Findling 1997)
The CGI was used to assess degrees of compulsive behaviour in
children. At two weeks post-treatment the CGI performance revealed a non-significant difference between the treatment and control groups ( .20, 95%CI= -.92, 1.32). At four weeks post-treatment onset a non-significant difference emerged in favour of the
treated group ( .10, 95% CI= -1.08,1.28).
Obsessive-Compulsive Behaviour (Findling 1997)
The OCS was used to assess children’s compulsive behaviours.
Findling et al reported no significant difference between the treated
and control groups at either the two week (.30, 95%CI= -5.41,
4.81) or four week interval of measurement post-treatment ( 2.30,
95% CI= -6.52,1.92).
Teacher rating of hyperactivity (Findling 1997)
The TRS is an observational teacher rating scale of child behaviour.
For this study, Findling 1997 used only the seven items assessing
the hyperactivity factor. Results of the rating by teachers revealed
a non-significant difference between the experimental and control
conditions at two and four weeks post-treatment ( .60, 95% CI=

-6.82,8.02 and .60, 95% CI= -6.25,7.45), respectively. However,
it should be pointed out that 25% of the TRS questionnaires were
not completed and the authors did not indicate at which time or
for which child (baseline or placebo lead-in) the questionnaire was
not completed.
Parent rating of impulsivity-hyperactivity (Findling 1997)
The PRS is a parent observational rating scale of children’s impulsivity-hyperactivity behaviour. Results of these observations revealed no significant difference between the experimental and control groups at either two or four weeks post-treatment onset ( -.30,
95% CI= -3.04,3.64 and .30, 95% CI= -3.88, 3.28), respectively.
As with the TRS observations, 16.7% of the PRS questionnaires
were not completed. No follow-up measurements were reported
subsequent to the treatment period. These analyses were compared
to analyses performed in the trial report and all effects were likewise found to be non-significant.
Kuriyama 2002
Three components of the WISC-III performance were reported
including Verbal IQ, Performance IQ and Total IQ (Kuriyama
2002). An analysis of the group performances for these (see
Analysis 2.1, Analysis 3.1, and Analysis 1.1 ) revealed no significant effects for any of the measures reported (see also Table 1, calculated using individual patient data supplied by authors). This is
in contrast to the authors’ stated findings, a discrepancy which can
be accounted for by differences between groups at baseline, and investigators’ use of change scores in compensation. The authors of
Kuriyama 2002 reported ’net gains in IQ or SQ scores’, calculated
as follows: “net gain in IQ or SQ scores=(the postintervention IQ
or SQ scores of the pyridoxine group minus the baseline IQ or
SQ scores of the pyridoxine group) minus (the postintervention
scores of the placebo group minus the baseline IQ or SQ scores
of the placebo group). Student’s t-tests were used to compare the
net gain in IQ or SQ scores between the pyridoxine and placebo
groups. Analysis of covariance (ANCOVA) was used to add adjustment for potential confounders.’ Net gain in verbal IQ scores
in the pyridoxine group as relative to the placebo group showed a
significant difference (5.2, 95% confidence interval 0.2 to 10.3).
Kuriyama concluded that this study ’demonstrated that pyridoxine was associated with improvement in the verbal IQ scores. This
result suggests that the subgroup of PDDs might have a similar
pathophysiological mechanism to pyridoxine-dependent epilepsy’
but the authors themselves warned that their results should be ’interpreted with caution because [of ] the small sample size... and
because it was ’a short-term study for four weeks. A long-term
study of the beneficial and adverse effects of pyridoxine is necessary’ (Kuriyama 2002).
Adverse events
It has been reported that a long-term administration of pyridoxine
may induce adverse effects such as a sensory peripheral neuropathy
(Schaumberg 1983), but no such effects were reported in these
(relatively short-term) studies. Findling 1997 reported some side

Combined vitamin B6-magnesium treatment in autism spectrum disorder (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

7

effects, but only during the placebo phases of the study (there
were a few reports of upper respiratory infection and one each of
headache, increase in bedwetting, and decrease in appetite).

DISCUSSION
This review is limited to three studies representing a total of 28
participants with autism spectrum disorder.
Sample size is problematic in this review. Since all three included
studies had small numbers of participants, the results obtained
may in part be due to a lack of power to detect group differences.
Future research should be conducted using appropriately large
sample sizes in order to assess any changes in measured performances in a reliable way. This may be particularly important if the
outcome measures do not have appropriately robust psychometric
properties.
Analysis could be accomplished for only one of the three included
studies (Findling 1997). Of the ten measures post-treatment, only
one (the CPRS score at four weeks, as reported in the data table)
showed a significant difference between the treated and control
group performances. The discrepancy between the apparently significant data reported for the CPRS measure of behaviour at four
weeks and the authors’ conclusion that the intervention produced
no significant differences calls into question the accuracy of the
data reported in the tables. While such a finding, if accurate, may
suggest that a longer treatment period might produce more positive effects for the CPRS measure, it must be remembered that all
other measures revealed no significant differences. Findling et al
did present a summary of the effect of time on the five measures.
It was concluded that there were no significant differences across
the 10 weeks of treatment (Findling 1997). In addition, the two
measures of compulsive behaviour yielded similar results. No significant differences emerged between the treatment and control
conditions at either two or four weeks post-treatment. The teacher
and parent ratings are even more difficult to interpret due to the
lack of specificity regarding the completion of the questionnaires,
as reported above. All of the missing questionnaires may have come
from the treatment period and the values presented may reflect
the two participants who were dropped from the treatment arm
of the study, while the values representing the treatment periods
were based on less than the total sample (10 participants). Correspondence with the author did not yield clarification on this issue.
Analysis of Kuriyama is difficult due to small sample size (n=8)
(substantially underpowered) and in the case of the VIQ and TIQ
scores, even positive effects may be misleading (Kuriyama 2002).
Also, the diagnostic classification of the participants is markedly
different from Findling 1997 in that the children in Kuriyama’s
study are typically considered to be higher functioning than children diagnosed with autism. Both Asperger Syndrome (AS) and

PDDNOS have different developmental histories and differential
diagnosis characteristics. The label of AS and PDDNOS do place
children so diagnosed under the umbrella of ’autism spectrum
disorder’, but they are functionally less severe and often qualitatively different in their deficit abilities; moreover, the investigators
themselves emphasised the use of their work as hypothesis-generating for those interested in the pathophysiological mechanisms
in PDDs.
Several important issues were not addressed in the studies reviewed
that might fall into the category of confounding factors, and future
research should certainly attempt to address many of these. For
example, the age range for these studies may not have been sensitive
to response variations in accounting for treatment effects. The
age range for studies was quite large (Tolbert’s inclusion criteria
went from 6 to 18 years while Findling’s participants were between
3 and 13 years of age and Kuriyama’s 8 to 12) (Tolbert 1993,
Findling 1997, Kuriyama 2002). In Findling’s study, two of the
five participants of the treatment arm of the study were six or
more years older than the eldest of the remaining participants.
Excluding these two older participants reduces the mean age of
the participants by more than 20 months. Such a period of time
is not inconsequential in the development of young children and
might lead to a different level of response.
Considering the severity of the condition, some individuals with
autism may need longer treatment periods in order to benefit from
treatment, and future research should address this issue. While
Findling 1997 measured outcomes at two and four week intervals,
no rationale was given as to why the total treatment period of four
weeks was established. It could be that longer treatment would
provide a greater response variation for some individuals. Furthermore, this response variation may be an interactive factor with
other variables such as age, severity, or outcome. Lastly, the nature
of the outcomes measured should be considered. Tolbert et al did
provide for a measure of quality of life using the R-F Scale and
concluded that no significant differences were observed between
treatment and placebo conditions (Tolbert 1993). However, Findling et al assessed outcomes that sought to measure improvement
in core features of autism, such as behaviour rating, hyperactivity,
and compulsiveness (Findling 1997). Future research should take
into account measurement of other meaningful outcomes such as
quality of life, educational readiness, independence and daily living skills.

AUTHORS’ CONCLUSIONS
Implications for practice
No changes in conclusions resulted with the updated version of this
review (2005). Due to the small number of studies, the methodological quality of studies, and small sample sizes, no recommendation can be advanced based on this review regarding the use of
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B6-Mg as a treatment for autism. There is simply not sufficient
evidence to demonstrate treatment efficacy.

large sample studies may not be feasible, multiple smaller sample
studies as multi-centre trials are feasible. Such a research model
would allow for the aggregation of data across studies to increase
the power of the analysis and findings.

Implications for research
This review was able to identify a total of 19 studies that have
attempted to address the efficacy of vitamin B6 interventions. As
only three studies were constructed in such a manner as to reflect
the standards of high quality research design, the most pressing
need is to develop well-controlled studies to adequately assess the
effectiveness of B6-Mg as an intervention for treating individuals
with autism. The major problem facing any research program in
this area is the low incidence of autistic participants. Even though
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CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]
Findling 1997
Methods

Randomized, double blind placebo-controlled, crossover trial. Following a 2 week pre-randomization
placebo lead-in period

Participants

12 participants enrolled, 10 (9 boys, 1 girl) completed program; mean age 6yrs 3 mo, range 3 yrs old to
12.9 years old

Interventions

1. B6+Mg (4 weeks) then Placebo (4 weeks)2.Placebo (4 weeks) then B6+Mg (4 weeks)Dosage: B6: 30mg/
kg/day (max =1gram);Mg:10mg/kg/day (max =350mg/day)

Outcomes

Performance on CARS, CGI, CPRS, OCS scales

Notes

B

Risk of bias
Bias

Authors’ judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Kuriyama 2002
Methods

Randomised double blinded placebo controlled trial. Outcome assessors and statistician also blinded

Participants

15 children with PDD recruited initially. All had been diagnosed with PDD (two with Asperger syndrome)
and also demonstrated features of a ’subgroup of children with PDDs who exhibit clinical features similar
to those of pyroxidine dependent epilepsy but do not have a history of seizures’. Then, 2 were excluded
because of history of epilepsy; 2 because they were already using B-complex vitamins, 3 because their IQs
were not measurable. 8 (4 males, 4 females) children remained. Mean age 10 years 6 months (SD = 1 year
8 months). Placebo group of 2 males, 2 females. Mean age 10 years 10 months (SD = 1 year). For both
groups, mean body weight was 44.5 (SD = 16.3) and 44.5 (SD = 18.3) kg, mean verbal IQ scores 74.3
(SD = 22) and 77.5 (SD = 15), mean performance IQ scores 78.8 (SD = 30.8) and 68.8 (SD = 5.2) and
mean Social Quotient (SQ) scores 73.5 (SD = 14.6) and 81 (SD = 11.9), respectively

Interventions

1. B6 100 mg daily for 2 weeks, then twice a day 100 mg each time, for two weeks
2. Placebo in identical powder form. Note compliance was measured by parent report and by blood
measurements after the trial
3 Parents were asked to complete a diary, recording any change in their child’s clinical signs or behaviour

Outcomes

IQ and social quotient SQ scores
IQ scores measured using Wechsler Intelligence Scales for Children -III (WISC-III) test 9. This test assigns
both verbal IQ scores and performance IQ scores. All IQ tests were conducted on each patient by the
clinical psychologist both at baseline and at end of fourth week of medication. The standard score of each
IQ has a mean of 100 and a standard deviation of 15.
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Kuriyama 2002

(Continued)
SQ scores were measured with the Social Maturity Scale (SM) test. 10 SQ scores were calculated as solcial
age divided by calendar age. All SM tests were assessed by patients’ parents

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Tolbert 1993
Methods

Randomized double-blind placebo controlled,
asymmetric cross-over trial; 10 week treatment blocks

Participants

Treated participants:10 males & 5 females diagnosed using DSM-III-R criteria (age range, 6 to 18)

Interventions

1.B6+Mg (20 weeks) then Placebo 10 (weeks)
2.B6+Mg (10 weeks) then Placebo (10 weeks)then B6+Mg (10 weeks)
Dosage: B6: 200mg/70kg weight
Mg: 100mg/70kg weight

Outcomes

Sensory-motor;
social behaviour; affective behaviour; sensory responses; language

Notes

Reported data not in useable form for analysis; Control group not randomly assigned

Risk of bias
Bias

Authors’ judgement

Support for judgement

Allocation concealment?

Unclear risk

B - Unclear

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Barthelemy 1980

lack of random group assignment to conditions

Barthelemy 1981

non-random group assignment

Barthelemy 1983

non-random group assignment
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(Continued)

Barthelemy 1985

non-random group assignment

Bönisch 1968

varied diagnosis for participants; no control condition

Jonas 1984

non-random group assignment

Lelord 1978

non-random group assignment; didn’t measure behaviour change

Lelord 1981

open trial; non-random group assignment

Lelord 1982

open trial; non-random group assignment

Martineau 1981

non-random group assignment; non-comparable group comparison

Martineau 1982

non-random group assignment; didn’t measure behavioral change

Martineau 1985

non-random group assignment; didn’t measure behavioural change

Martineau 1988

open trial; non-random group assignment

Martineau 1989

open trial; non-random group assignment

Menage 1992

open trial; non-random group assignment

Rimland 1978

open study: non-random group assignment of participants
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DATA AND ANALYSES

Comparison 1. Intelligence quotient (IQ)

Outcome or subgroup title

No. of
studies

No. of
participants

1

8

1 B6 versus placebo

Statistical method
Mean Difference (IV, Fixed, 95% CI)

Effect size
5.25 [-20.13, 30.63]

Comparison 2. Verbal intelligence quotient

Outcome or subgroup title

No. of
studies

No. of
participants

1

8

No. of
studies

No. of
participants

1

8

1 B6 versus placebo

Statistical method
Mean Difference (IV, Fixed, 95% CI)

Effect size
2.0 [-18.22, 22.22]

Comparison 3. Perfomance IQ

Outcome or subgroup title
1 B6 versus placebo

Statistical method
Mean Difference (IV, Fixed, 95% CI)

Effect size
-6.75 [-26.85, 13.
35]

Comparison 4. Social quotient (SQ)

Outcome or subgroup title
1 B6 versus placebo

No. of
studies

No. of
participants

1

8

Statistical method
Mean Difference (IV, Fixed, 95% CI)
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-12.5 [-30.35, 5.35]
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Analysis 1.1. Comparison 1 Intelligence quotient (IQ), Outcome 1 B6 versus placebo.
Review:
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Comparison: 1 Intelligence quotient (IQ)
Outcome: 1 B6 versus placebo

Study or subgroup

Pyroxidine (B6)

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

Kuriyama 2002

4

82.75 (23.67)

4

77.5 (10.5)

Total (95% CI)

4

Mean
Difference

Weight

IV,Fixed,95% CI

IV,Fixed,95% CI

4

100.0 %

5.25 [ -20.13, 30.63 ]

100.0 %

5.25 [ -20.13, 30.63 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Verbal intelligence quotient, Outcome 1 B6 versus placebo.
Review:

Combined vitamin B6-magnesium treatment in autism spectrum disorder

Comparison: 2 Verbal intelligence quotient
Outcome: 1 B6 versus placebo

Study or subgroup

Pyroxidine (B6)

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

Kuriyama 2002

4

85.5 (17.56)

4

83.5 (10.83)

Total (95% CI)

4

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

4

100.0 %

2.00 [ -18.22, 22.22 ]

100.0 %

2.00 [ -18.22, 22.22 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Perfomance IQ, Outcome 1 B6 versus placebo.
Review:

Combined vitamin B6-magnesium treatment in autism spectrum disorder

Comparison: 3 Perfomance IQ
Outcome: 1 B6 versus placebo

Study or subgroup

Pyroxidine (B6)

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

Kuriyama 2002

4

73.5 (17.56)

4

80.25 (10.59)

Total (95% CI)

4

Mean
Difference

Weight

IV,Fixed,95% CI

IV,Fixed,95% CI

4

100.0 %

-6.75 [ -26.85, 13.35 ]

100.0 %

-6.75 [ -26.85, 13.35 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Social quotient (SQ), Outcome 1 B6 versus placebo.
Review:

Combined vitamin B6-magnesium treatment in autism spectrum disorder

Comparison: 4 Social quotient (SQ)
Outcome: 1 B6 versus placebo

Study or subgroup

Pyroxidine (B6)

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

Kuriyama 2002

4

80.5 (14.5)

4

93 (11.02)

Total (95% CI)

4

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

4

100.0 %

-12.50 [ -30.35, 5.35 ]

100.0 %

-12.50 [ -30.35, 5.35 ]

Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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